The COVID-19 pandemic compelled the industry to re-examine the way it conducted clinical trials, engaged with patients, and promoted to HCPs. Companies began to explore decentralized clinical trials, new non-personal promotion strategies, virtual customer engagement strategies, and new ways to engage with the patient — all with an eye toward replacing status quo processes and technologies. The result was the accelerated development of new clinical and commercial technologies and data with the ultimate goal of bringing new therapies to patients faster.